Alnylam Pharmaceuticals

Latest news

• Alnylam Announces FDA Approval of Amvuttra (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
  20 March 2025
• Alnylam Announces FDA Approval of Supplemental New Drug Application for Oxlumo (lumasiran) in Advanced Primary Hyperoxaluria Type 1
  7 October 2022
• FDA Approves Amvuttra (vutrisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
  13 June 2022
• Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
  4 April 2022
• Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
  21 January 2022
• Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis
  24 June 2021
• Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran
  19 April 2021
• Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
  7 January 2021
• FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1
  24 November 2020
• Alnylam Presents Positive Phase 3 Results from ILLUMINATE-A Study of Lumasiran, an Investigational RNAi Therapeutic for Treatment of Primary Hyperoxaluria Type 1
  7 June 2020

Drugs Associated with Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. manufactures, markets and/or distributes more than 3 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.